On July 20, 2022, Abbott reported Q2 sales of $11.3 billion (an increase of 10.1% year-over-year and 14.3% on an organic basis) on adjusted diluted earnings per share (EPS) of $1.43.
Summary: Abbott’s Q2 2022 sales grew by 10.1% as compared to the same period in 2021. Abbott reports its sales across four segments: Nutrition, Diagnostics, Established Pharmaceuticals, and Medical Devices.
The company reported earnings from operations of $2.38 billion during Q2 2022, resulting in GAAP operating margins of 21.1%. On the bottom line, the company reported a diluted EPS of $1.14, whereas the adjusted diluted earnings came to $1.43 per share.
Guidance: Abbott is raising its projected full-year 2022 diluted earnings per share under GAAP to at least $3.50. Abbott is also raising its projected adjusted diluted earnings per share to at least $4.90 for the full-year 2022.
United States of America
United States of America
Ireland
Germany
United States of America
Germany
United States of America
United States of America
Netherlands
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward